地拉罗司对铁质积聚有多大效果？

It is an oral iron chelator that was approved by the FDA in 2005 for the treatment of chronic iron overload caused by blood transfusion. Deferasirox is from Novartis. In January 2013, the FDA approved the expanded indication of deferasirox to treat chronic iron overdose caused by Non-Transfusion Dependent Thalassemia Syndromes (NTDT), making deferasirox the first drug to treat this indication. So, how effective is deferasirox on iron buildup?

The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of deferasirox in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that deferasirox can improve organ function in patients with iron overload. The TELESTO study results released at ASH2018 also proved that deferasirox continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%. EPIC is currently the largest prospective, open, single-group, global multi-center clinical study designed for patients with iron overload. A total of 341 MDS patients were enrolled, and it could reduce serum ferritin by an average of 372 μg/L in 3 months.

In summary, iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, it is convenient to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.